1. Artificial oral fluid characterisation: Potential for use as a reference matrix in drug testing
- Author
-
Kim Wolff, Alison Woffendin, Duncan Harding, Fan Gong, David A. Cowan, Andrew Smart, Ivana Gavrilović, and Alessandro Musenga
- Subjects
Drug ,Materials science ,Quality Assurance, Health Care ,media_common.quotation_subject ,Pharmaceutical Science ,01 natural sciences ,Analytical Chemistry ,Surface-Active Agents ,03 medical and health sciences ,Matrix (mathematics) ,0302 clinical medicine ,Anti-Infective Agents ,Humans ,Transition Temperature ,Environmental Chemistry ,030216 legal & forensic medicine ,Specific Gravity ,Spectroscopy ,media_common ,Chromatography ,Viscosity ,business.industry ,010401 analytical chemistry ,Mucins ,Hydrogen-Ion Concentration ,Body Fluids ,0104 chemical sciences ,Substance Abuse Detection ,Freezing-point depression ,Oral fluid ,Salts ,business ,Quality assurance ,Specific gravity - Abstract
Quality assurance schemes for drug-screening programmes require access to large quantities of biological matrices for reference or control samples. This presents problems when the availability of a matrix, such as oral fluid (OF) for screening or for confirmatory purposes, limits the collection of large volumes. In such cases, synthetic alternatives of OF may provide a solution. The preparation of an artificial (synthetic) oral fluid (AOF) was conducted by dissolving its components (salts, surfactant, antimicrobial agent and mucin) in water. We characterised the physical properties of AOF to determine its suitability as a matrix for quality assurance purposes. The evaluation of pH, specific gravity (SG), conductivity (mS cm-1 ), freezing point depression (°C), light-scattering and kinematic viscosity (mm2 s-1 ) showed AOF to be a stable, reliable matrix. Synthetic OF was prepared using components (mucin, surfactants and so on) obtained from different suppliers and a comparison was performed. Our results suggest that AOF is a feasible matrix for the preparation of quality assurance samples for confirmatory or drug screening programmes.
- Published
- 2020
- Full Text
- View/download PDF